

BUREAUX 54 IMM A1 RESIDENCE RYAD ANFA BD OMAR EL KHAYAM CASA FINANCE CITY, Casablanca, Maroc

T: +212 529 153 330 www.bakertilly.ma

IF : 20696242 RC : 362941 CNSS : 5230686 TP : 35592412 ICE : 001624536000055

SUN PHARMACEUTICALS MOROCCO LLC SARLAU

GENERAL REPORT OF THE INDEPENDENT AUDITOR ON PROVISIONAL ACOUNTS

YEAR ENDED MARCH 31ST, 2022

ADVISORY · ASSURANCE · TAX · LEGAL



(This is a free translation into English of our audit report signed and issued in French and is provided solely for the convenience of English speaking users. This report should be read in conjunction and construed solely in accordance with, Moroccan law and Moroccan professional standards).

GENERAL REPORT OF THE INDEPENDENT AUDITOR ON PROVISIONAL ACOUNTS

YEAR FROM APRIL 1st, 2021 TO MARCH 31st, 2022

To the Shareholder of SUN PHARMACEUTICALS MOROCCO LLC SARLAU CASABLANCA

AUDIT OF THE FINANCIAL STATEMENTS

Opinion

In accordance with the terms of our appointment as auditors, we have audited the accompanying financial statements of the company SUN PHARMACEUTICALS MOROCCO LLC SARLAU, including the balance sheet and the profit and loss account relating to the financial year ended March 31st, 2022. These financial statements show an amount of net equity of KMAD 19 421 including a net profit of KMAD 4 863.

In our opinion, the financial statements referred to in the first paragraph above are regular, sincere and give a true and fair view of SUN PHARMACEUTICALS MOROCCO LLC SARLAU's assets, liabilities and financial position at March 31st,2022, and of its operations for the year then ended, in accordance with the accounting principles generally accepted in Morocco.

Basis of opinion

We conducted our audit in accordance with the Moroccan auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Morocco, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Responsibilities of Management and Those Charged With Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Moroccan accounting standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Moroccan auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with Moroccan auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures in response to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

The independent auditor

Baker Tilly Majer Audit

M. Mohamed Hamdache

Partner

31-03-22

Tableau N° 1 Société : SUN PHARMA MOROCCO LLC SARLAU Article IS : 40256039

Balance Sheet (Assets)

ASSETS		PRIOR YEAR		
	Gross Amount	Amortisation or depreciation	Net amount	Net amount
CAPITALIZED EXPENSES (A)	163.353,00	163.353,00	0,00	
Preliminary expenses	163.353,00	163.353,00		
Deferred expenses on several years				
Premium of debentures refund				
INTANGIBLE FIXED ASSETS (B)	66.741,00	66.741,00	0,00	659,55
Research and development	00.741,00	00.771,00		
Patents, Trademarks, and similar rights	66.741,00	66.741,00		659,55
	00.741,00	00.741,00		037,33
Goodwill				
Other Intangible Assets				45.400.045.50
TANGIBLE FIXED ASSETS(C)	15,040,836,96	4.257.021,27	10.783.815,69	10.498.345,72
Land				
Buildings				
Industrial fixtures and equipement	10.326.653,21	2,438.485,14	7.888.168,07	8.381.685,78
Transportation equipement				
Office equipment and furniture	4.714.183,75	1,818.536,13	2.895.647,62	2.116.659,94
Other tangible fixed assets				
Tangible fixed assets in progress				
LONG TERM INVESTMENTS (D)	1.907.358,16	0,00	1.907.358,16	1,011.425,16
Long term loans	1			
Other financial assets	1.907.358,16		1,907,358,16	1.011.425,16
	1.707.336,10		1.707.336.10	1,011.425,10
Investments				
Other investments				
UNREALISED EXCHANGE RATE LOSSES (E)				
Unrealised exchange rate losses (from long term asse				
Unrealised exchange rate losses (from long term liab				
TOTAL I (A+B+C+D+E)	17.178.289,12	4.487.115,27	12.691.173,85	11.510.430,43
INVENTORIES (F)	142.375.724,04	48.109.873,20	94.265.850,84	57.529.668,44
Merchandises	116,833,752,70	34.624.993,62	82.208.759,08	48.517.006,86
Raw materials and furnitures	20.949.929,59	10,632.022,17	10.317.907,42	8.125.740,67
Work in progress				
Intermediate and residual products				
Finished products	4.592.041,75	2.852.857,41	1.739.184,34	886.920,91
CURRENT ASSETS(G)	168.633.166,31	0,00	168,633,166,31	168,189,449,71
-		0,00		4,977.864,03
Advances payments to suppliers and other debtors	2.629.976,50		2.629.976,50	
Trade accounts receivable	147.626.891,86		147.626.891,86	144.674.658,35
Personnel	556.297,07		556.297,07	501.559,03
Taxes	17.202.863,06		17.202.863,06	17.486.959,41
Shareholders Current accounts				
Others debtors	210.504,92		210.504,92	210.504,92
Deferral accounts	406.632,90		406.632,90	337.903,97
MARKETABLE SECURITIES (H)				
UNREALISED EXCHANGE RATE LOSSES (I)	11.350.296,41		11.350.296,41	3.907.585,78
(Current)				
TOTAL II (F+G+H+I)	322,359,186,76	48.109.873,20	274.249.313,56	229.626.703,9
CASH AND CASH EQUIVALENTS (Assets)	8.909.220,82	0,00	8.908.701,82	39.088.995,8
	0.707.220,02	0,00	5.7 55.7 61,02	27,000,770,0
Checks and other instruments to be cashed	0.000.701.00		0.000.701.00	20.014.720.7
Cash on Bank	8,908,701,82		8.908.701,82	38.914.730,7
Cash on hand	519,00		519,00	174.265,0
TOTALIII	8.909.220,82	00,0	8.909.220,82	39.088.995,8
TOTAL ASSETS I+II+III	348.446.696,70	52.596.988,47	295.849.708,23	280,226,130,1
	, 0, 0 , 0 , 0			

Article IS: 40256039

Balance Sheet (Liabilities) (Modèle Normal)

(Modèle Norm	al)	
LIABILITIES	CURRENT YEAR	PRIOR YEAR
Shareholder's equity (A)		
Common stock (1)	12.235.300,00	12.235.300,00
(Minus) Common stock subscribed but not called-up		
Issuance, merger and contribution premium		
Revaluation reserve		
Legal reserve		
Others reserves		
Profit/ loss account brought forward (2)	2.322.937,22	-11.830.522,82
Not yet allocated income (2)		
of the year	4.863.115,81	14.153.460,06
Total Shareholders Net Equity (A)	19.421.353,03	14.558.237,24
RELATED EQUITY (B)	0,00	0,00
Investment Subsidy		
Regulatory provisions		
FINANCIAL LIABILITIES (C)	0,00	0,00
Debenture Loans		
R Other financial liabilities		
4		
PROVISION FOR CONTINGENCIES AND LOSSES(D)	0,00	0,00
Provision for contingencies	3,00	
N Provision for losses		
UNREALISED EXCHANGE RATE GAINS (Non current) (E)	0,00	0,00
Unrealised exchange rate gains from long term assets	0,00	0,00
Unrealised exchange rate gains from long term labilities		
officerised exchange rate gains from long term habilities		
Total I(A+B+C+D+E)	19.421.353,03	14.558.237,24
Total (ATBTOTE)	17.421.333,03	14.000.207,24
CURRENT LIABILITIES (F)	230.279.112,63	253.712.693,21
Trade accounts payable	155.067.372,04	160.357.696,32
C Clients in credit, Advance payments received	133.007.372,04	18.981.469,66
Personnel	4 226 246 29	
	4.236.346,28	4.855.939,56
R Social security liabilities	2.257.180,37	1.953.898,21
Taxes	13.519.230,35	16.780.350,24
U Shareholders current accounts	55.196.565,51	50.783.339,22
L Others debts		
A Deferral accounts		(011=10-1
OTHER PROVISION FOR CONTINGENCIES AND LOSSES (G)	14.860.398,69	6.844.712,98
T UNREALISED EXCHANGE RATE GAINS (Current) (H)	2.308.670,90	5.110.486,73
Total II (F+G+H)	247.445.764,14	265.667.892,92
T CASH LIABILITIES	0,00	0,00
Discounts credit		
E Short term credit facility		
S Bank Overdrafts	28.982.591,06	
Total III		
TOTAL LIABILITIES I+II+III	295.849.708,23	280.226.130,16

Debtor share capital (-) Income (+) Loss (-)

Tableau N°2 Société : SUN PHARMA MOROCCO LLC SARLAU Article IS : 40256039

INCOME STATEMENT

П		CURRENT YEAR				
		ITEM	Related to the period	Related to the prior periods	Net amount	PRIOR YEAR Net amount
			1	periods 2	3=2+1	4
	ı	OPERATING REVENUE				
		Sales of merchandise	267.163.421,71		207.103.421,71	233.159.542,72
		Sales of goods and services	36.822.896,64		36.822.896,64	36.452.013,08
		Turnover	303.986.318,35		303.986.318,35	269.611.555,80
		Finished Goods inventory change (+/-) (1)	1.573.842,43		1.573.842,43	-164.907,37
		Self constructed capital asset				
		Operating Subsidy				
		Others operating income	19,034.109,26		19.034.109,26	13.579.233,29
EXPLOITATION		Reversal of operating provisions charges transfer	36.270.812,56		36,270.812,56	22.010.507,48
IAI		Total i	360.865.082,60		360.865.082,60	305.945.389,20
2.0	Ш	OPERATING EXPENSES				
Ж		Purchase of goods for resale (2)	145.319.082,70		145.319.082,70	131.763.710,42
		Purchase of materials and supplies (2)	10.466.777,77		10.466.777,77	9.442.603,67
		Other external expenses	101.217.802,12	266 380,32	101 484 182,44	82 966 829 61
		faxes	2.177.880,41		2.177.880,41	112.545,51
		Personnel expenses	36,282.087,71		36.282.087,71	33,402,792,47
		Other operating expenses				
		Operating allowances (for depreciation and risks)	49.429.033,00		49.429.033,00	37.421.245,85
		Total II	344.892.663,71	266.380,32	345.159.044,03	295.769.825,83
	Ш	OPERATING INCOME / LOSS (I - II)			15.706.038,57	10.175.563,37
	IV	FINANCIAL REVENUE				
		Revenue from investment and others				
		Exchange gains	4,398.362,72		4.398.362,72	4.155.455,90
		Interests and other financial revenue	202.975,08		202.975,08	718.577,83
l "		Reversal of financial provisions - charges transfer	6.898.272,46		6.898.272,46	17.865.169,73
FINANCIER		Total IV	11.499.610,26		11.499.610,26	22.739.203,46
NAN	V	FINANCIAL EXPENSES				
ī.		Interests expenses	1.340.720,36		1.340.720,36	1.246.864,43
		Exchange losses	2.982.057,37		2.982.057,37	2.013.394,77
		Other fianancial expenses				
		Financial allowances	14.863.605,42		14.863.605,42	7.019.992,06
		Total V	19.186.383,15		19.186.383,15	10.280.251,26
	VI	FINANCIAL INCOME (IV-V	-7.686.772,89		-7.686.772,89	12.458.952,20
L	VII	ORDINARY INCOME (III+VI	8.285.646,00	-266.380,32	8.019.265,68	22.634.515,57

As of

31-03-22

31-03-22

As of

INCOME STATEMENT

		CURRENT YEAR			
	ITEM	Related to the period	Related to the prior periods	Net amount	PRIOR YEAR Net amount 4
VII	ORDINARY INCOME (report)	8.285.646,00	-266.380,32	8.019.265,68	22,634,515,57
VIII	EXCEPTIONAL REVENUE	1.067.571,70		1.067.571,70	
	Revenue from assets disposal	0,00		00,0	00,0
	Balancing Subsidy	0,00		0,00	0.00
	Reversal of Investment Subsidy	0,00		0.00	0,00
	Other extraordinary revenue	1.067.571.70		1.067.571,70	6,66
1	Reversal of extraordinary provisions- charges transfer	0,00		0,00	0,00
	Total VIII	1.067.571,70	0,00	1.067.571,70	6,66
IX	EXCEPTIONAL EXPENSES				
0 0 0	Net value of sold assets	0,00		00,0	0,00
Ö	Granted Subsidies	0,00		0.00	0,00
0	Others extraordinary expenses	-0,43		-0,43	950.922,17
	Extraordinary allowances	0,00		0,00	00,0
	Total IX	-0,43	0,00	-0,43	950.922,17
λ	EXCEPTIONAL INCOME / EOSS (VIII - IA)	1.067.572,13		1.067.572,13	-950.915,51
ΧI	INCOME / LOSS BEFORE TAXES(VII+X)	9.353.218,13	-266.380,32	9.086.837,81	21.683.600,06
XII	INCOME TAX	4.223.722,00		4.223.722,00	7.530.140,00
XII	NET INCOME / LOSS (XI - XII)	5.129.496,13	-266.380,32	4.863.115,81	14.153.460,06

1 1	TOTAL OF REVENUES .(I+IV+VIII)	373.432.264,56		373.432.264,56	328.684.599,32
1 1	TOTAL OF EXPENSES .(II+V+IX+XII)	368.302.768,43	266.380,32	368.569.148,75	314.531.139,26
XVI	NET INCOME	5.129.496,13	-266.380,32	4.863.115,81	14.153.460,06